 Shares of Zymeworks Inc. ZYME, 1.89 rallied 1.5 in morning trading Friday, after the biopharmaceutical company said it rejected the unsolicited, opportunistic, non-binding 10.50-per-share buyout bid by activist investor All Blue Falcons FZE. The company said it determined that the bid by the UAE-based investment holding company significantly undervalues the company and its prospects, and lacks credibility by offering no information regarding funding. 